Keyphrases
Everolimus
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Phase 1 Study
100%
Sorafenib
100%
Dose Level
77%
Twice Daily
44%
Maximum Tolerated Dose
22%
Rash
22%
Partial Response
22%
Disease Progression
11%
Pharmacokinetics
11%
Diarrhea
11%
Dose-limiting Toxicity
11%
Antitumor Activity
11%
Hypertension
11%
Pancreatitis
11%
Tyrosine Kinase Inhibitor
11%
Systemic Therapy
11%
MTOR Inhibitor
11%
Stable Disease
11%
Patient Dose
11%
Hypophosphatemia
11%
Antitumor Effect
11%
Lipase
11%
Pharmacokinetic Analysis
11%
Hypothyroidism
11%
Escalating Dose
11%
Patients Included
11%
Previously Untreated Patients
11%
Response Evaluation Criteria in Solid Tumors (RECIST)
11%
Hyperuricemia
11%
Patient-level
11%
National Cancer Institute Common Terminology Criteria for Adverse Events
11%
Gout
11%
Hand-foot Syndrome
11%
In(III)
11%
Treatment-related Adverse Events
11%
Pharmacology, Toxicology and Pharmaceutical Science
Everolimus
100%
Sorafenib
100%
Renal Cell Carcinoma
100%
Adverse Event
22%
Rash
22%
Maximum Tolerated Dose
22%
Pharmacokinetics
22%
Antitumor Activity
11%
Pancreatic Lipase
11%
Malignant Neoplasm
11%
Diarrhea
11%
Solid Malignant Neoplasm
11%
Disease Exacerbation
11%
Protein Tyrosine Kinase Inhibitor
11%
Kidney Metastasis
11%
Mammalian Target of Rapamycin Inhibitor
11%
Pancreatitis
11%
Gout
11%
Hand Foot Syndrome
11%
Hypothyroidism
11%
Hyperuricemia
11%
Hypophosphatemia
11%
Diseases
11%